Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis

References

• Ayas M, Nassar A, Hamidieh AA, et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transplant. 2013;48(9):1168–1172. e-pub ahead of print 2013/04/02.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Estey E. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. Hematol Am Soc Hematol Educ Program. 2014;2014(1):21–33. e-pub ahead of print 2015/02/20.
   PubMed Web of Science ®Google Scholar
• Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012;120(7):1367–1379.
   PubMed Web of Science ®Google Scholar
• Hashmi S, Ahmed M, Murad MH, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016;3(1):e45–e52.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2015;13:10.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu J, Wei W. Advance in targeted immunotherapy for graft-versus-host disease. Front Immunol. 2018 May;9: DOI:10.3389/fimmu.2018.01087
   Web of Science ®Google Scholar
• Kurosawa S, Yamaguchi T, Oshima K, et al. Resolved versus active chronic graft-versus-host disease: impact on post-transplantation quality of life. Biol Blood Marrow Transplant. 2019;25(9):1851–1858. e-pub ahead of print 2019/05/28.
   Web of Science ®Google Scholar
• Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16(12):1611–1628. e-pub ahead of print 2010/07/06.
   PubMed Web of Science ®Google Scholar
• Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation. Blood. 1998;92(7):2288–2293. e-pub ahead of print 1998/09/25.
   PubMed Web of Science ®Google Scholar
• Wolff D, Ayuk F, Elmaagacli A, et al. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant. 2013;19(5):767–776. e-pub ahead of print 2013/02/05.
   PubMed Web of Science ®Google Scholar
• Assouan D, Lebon D, Charbonnier A, et al. Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease. Br J Haematol. 2018;181(5):687–689.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian -J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Choi J, Cooper ML, Alahmari B, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PloS One. 2014;9(10). DOI:10.1371/journal.pone.0109799
   Web of Science ®Google Scholar
• Betts BC, Abdel-Wahab O, Curran SA, et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by dendritic cell-stimulated human T cells, yet preserves immunity to recall antigen. Blood. 2011;118(19): 5330–5339.
   Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252. e-pub ahead of print 2016/03/31.
   PubMed Web of Science ®Google Scholar
• Kröger N, Alchalby H, Ditschkowski M, et al. Ruxolitinib as pretreatment before allogeneic stem cell transplantation for myelofibrosis. Blood. 2013;122(21):392.
   Web of Science ®Google Scholar
• Choi J, Ziga ED, Ritchey J, et al. IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120(19):4093–4103. e-pub ahead of print 2012/09/14.
   PubMed Web of Science ®Google Scholar
• Modi B, Hernandez-Henderson M, Yang D, et al. Ruxolitinib as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2019;25(2):265–269.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Langston AA, Kota VK, et al. Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant. 2018;53(7):826–831.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Higgins J, Altman DG, et al. Cochrane handbook for systematic reviews of interventions version 5.1. 0. 2011 (updated March 2011). The Cochrane Collaboration. 2011:2.
   Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donor, S. Transplantation. 1974;18(4):295–304.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956.
   PubMed Web of Science ®Google Scholar
• Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed). 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. e-pub ahead of print 1997/10/06.
   PubMed Web of Science ®Google Scholar
• Ai H, Fu YW, Wang YQ, et al. Safety and efficacy of ruxolitinib as a salvage regimen for patients with refractory acute and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2018;39(12):1026–1029.
   PubMedGoogle Scholar
• Bonmann S, Christopeit M, Wolschke C, et al. Ruxolitinib plus Extracorporeal Photopheresis (ECP) may increase response in steroid refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant. 2017;52:304–305.
   PubMed Web of Science ®Google Scholar
• Ecsedi M, Gerull S, Medinger M, et al. Efficacy of ruxolitinib in the treatment of steroid-refractory graft-versus-host disease. Praxis (Bern 1994). 2015;104:163–164.
   Google Scholar
• Ferreira AM, Pontes da Silva CA, Pereira AD, et al. Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. Bone Marrow Transplant. 2018;53(4):503–506.
   PubMed Web of Science ®Google Scholar
• Gomez VE, Gutiérrez VG, Caballero-Velázquez T, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multi-center survey study. Blood. 2017;130:1983–1983.
   Google Scholar
• Hurabielle C, Sicre de Fontbrune F, Moins-Teisserenc H, et al. Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease. Br J Dermatol. 2017;177(5):e206–e208.
   PubMed Web of Science ®Google Scholar
• Lupo-Stanghellini MT, Corti C, Guggiari E, et al. Promising efficacy and safety profile of ruxolitinib in highly pre-treated chronic GvHD patients. Bone Marrow Transplant. 2017;52:301.
   PubMed Web of Science ®Google Scholar
• Niittyvuopio R, Heiskanen J, Lindstrom V, et al. Ruxolitinib treatment for corticosteroid-resistant acute intestinal GVHD. Bone Marrow Transplant. 2017;52:306.
   Web of Science ®Google Scholar
• Poyatos-Ruiz LL, Vega-Coca MD, Flores-Moreno S, et al. Off-label use of ruxolitinib in refractory graft-versus-host disease after allogenic stem cell transplantation. Value Health. 2016;19(7):A576.
   Web of Science ®Google Scholar
• Spoerl S, Maas-Bauer K, Verbeek M, et al. Response to JAK 1/2 inhibition in patients with corticosteroid-refractory acute graft-versus-host disease. Blood. 2014;124(21):3934.
   Web of Science ®Google Scholar
• Syed Abd Kadir S, Wolschke C, Ayuk F, et al. JAK-inhibition to treat steroid-refractory acute and chronic graft versus host disease (SR-GvHD)-a single center experience. Bone Marrow Transplant. 2016;51:S381.
   Web of Science ®Google Scholar
• Zeiser R, Burchert A, Lengerke C, et al. Treatment of corticosteroid-refractory graft-versus-host disease with ruxolitinib in 95 patients. Blood. 2015;126(23):858.
   PubMedGoogle Scholar
• Zeiser R, Lengerke C, Spoerl S, et al. High response rates in patients treated with ruxolitinib for corticosteroid-refractory graft-versus-host disease: analysis including 13 transplant centers. Bone Marrow Transplant. 2015;50:S22.
   Web of Science ®Google Scholar
• Khandelwal P, Teusink-Cross A, Davies SM, et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2017;23(7):1122–1127.
   PubMed Web of Science ®Google Scholar
• Csanadi M, Agh T, Tordai A, et al. A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. Expert Rev Hematol. 2019;12(5):311–323. e-pub ahead of print 2019/04/09.
   PubMed Web of Science ®Google Scholar
• Mannina D, Kroger N. Janus kinase inhibition for graft-versus-host disease: current status and future prospects. Drugs. 2019;79(14):1499–1509. e-pub ahead of print 2019/07/31.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Hashimoto D, Hayase E, et al. Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. Blood. 2018;131(18):2074–2085.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American society of blood and marrow transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150–1163. e-pub ahead of print 2012/04/19.
   PubMed Web of Science ®Google Scholar
• Arai S, Margolis J, Zahurak M, et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant. 2002;8(3):155–160. e-pub ahead of print 2002/04/10.
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen S, Yang P, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10(1):182. e-pub ahead of print 2019/06/23.
   PubMedGoogle Scholar
• Krasowska-Kwiecien A, Gozdzik J, Jarocha D, et al. Mesenchymal stem cells as a salvage treatment for severe refractory graft-vs-host disease in children after bone marrow transplantation. Transplant Proc. 2019;51(3):880–889. e-pub ahead of print 2019/04/14.
   PubMed Web of Science ®Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Multicenter open-label phase 2 study of ibrutinib in chronic graft versus host disease (cGVHD) after failure of corticosteroids. Am Soc Hematol. 2016;128(22):LBA–3.
   Google Scholar
• Abedin S, McKenna E, Chhabra S, et al. Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(8):1689–1694. e-pub ahead of print 2019/04/10.
   PubMed Web of Science ®Google Scholar
• Von Bubnoff N, Ihorst G, Grishina O, et al. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). BMC Cancer. 2018;18(1):1132.
   PubMedGoogle Scholar
• Agh T, Csanadi M, Voko Z, et al. Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status. Expert Rev Hematol. 2019;12(5):295–309. e-pub ahead of print 2019/03/31.
   PubMed Web of Science ®Google Scholar
• González Vicent M, Molina B, González de Pablo J, et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results. Am J Hematol. 2018. DOI:10.1002/ajh.25376.
   PubMed Web of Science ®Google Scholar
• Lazaryan A, Weisdorf DJ, DeFor T, et al. Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors. Biol Blood Marrow Transplant. 2016;22(1):134–140.
   PubMed Web of Science ®Google Scholar